Mukka Proteins to hold 15th AGM on 18 Sep 2025; reports decline in FY25 consolidated revenue and profit
The announcement includes the annual financial results, which show a substantial decline in key financial metrics, alongside the notice for the Annual General Meeting and the decision not to recommend a dividend, which are all material events for investors.
The company reported a significant decline in both consolidated and standalone revenue and profit after tax for FY 2024-25, and the Board did not recommend any dividend for the fiscal year.
Mukka Proteins Limited has announced that its 15th Annual General Meeting (AGM) will be held on Thursday, 18 September 2025, at 3:00 P.M. (IST) via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). * The Annual Report for the financial year 2024-25 has been released. * The cut-off date for determining members eligible to vote at the AGM is Thursday, 11 September 2025. * The remote e-voting period is from Monday, 15 September 2025, at 9:00 A.M. to Wednesday, 17 September 2025, at 5:00 P.M. (IST).
Financial Performance for FY 2024-25 (compared to FY 2023-24): * Consolidated Revenue from Operations: ₹ 1,006.42 crore (₹ 10,064.16 million), a decline from ₹ 1,379.83 crore (₹ 13,798.29 million) in the previous year. * Consolidated Profit After Tax: ₹ 48.10 crore (₹ 480.97 million), a decline from ₹ 74.31 crore (₹ 743.05 million) in the previous year. * Standalone Revenue from Operations: ₹ 886.74 crore (₹ 8,867.43 million), a decline from ₹ 1,268.54 crore (₹ 12,685.43 million) in the previous year. * Standalone Profit After Tax: ₹ 41.68 crore (₹ 416.83 million), a decline from ₹ 62.76 crore (₹ 627.56 million) in the previous year.
Corporate Updates: * The Board has not recommended any dividend for FY 2024-25 to strengthen the financial position and augment working capital. * Ento Proteins Private Limited, an Associate Company, became a Subsidiary on 27 September 2024, with the Company's holding increasing from 50% to 74%. * MSFI (Bangladesh) Limited ceased to be an Associate Company on 17 December 2024, following the sale of investment.
In his message, the Managing Director and CEO, Kalandan Mohammed Haris, stated that FY 2024-25 was pivotal following the successful IPO in 2024. He mentioned significant strides in strengthening operational capabilities, expanding market presence, and delivering sustainable value. Looking ahead, the company remains committed to expanding its product portfolio, entering new geographic markets, and strengthening sustainability initiatives for sustained growth.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.